Theralase Technologies Inc. V.TLT

RE:RE:RE:New BCG-Unresponsive NMIBC Treatment Review Study

[skier59]

Where do you get a CR of 36% at 450 days for Rudvidar??
I see 27% at 360 days and 26% at 450 days as per the NR of October 7th.

wildbird1 wrote:

CancerSlayer wrote:

Eoganacht wrote:

European Urology Oncology

Available online 15 November 2024

David D’Andrea, Hugh Mostafid, Paolo Gontero, Shahrokh Shariat, Ashish Kamat, Alexandra Masson-Lecomte, Maximilian Burger, Morgan Rouprt

Unmet Need in Non–muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gurin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group

"A total of 57 studies published between 1998 and 2024, with 68 unique study arms and consisting of 2589 patients, were identified. The 3-mo overall response rate (ORR) across all studies, complete response rate (CRR) in concomitant carcinoma in situ (CIS) or CIS only disease, and recurrence-free rate (RFR) in papillary disease were estimated to be 52.4% (95% confidence interval [CI]: 45.4–59.2), 52.8% (95% CI: 42.9–62.6), and 26.4% (95% CI: 13.3–45.6), respectively. The 12-mo ORR, CRR, and RFR were estimated to be 78% (95% CI: 52.9–91.8), 27.8% (95% CI: 21.3–35.4), and 25.4% (95% CI: 18.2–34.2), respectively."



The study includes the toxicity events for all 4 BCG-Unresponsive NMIBC approved treatments. TLD1433 had better safety results (zero toxicity events) than all approved treatments.

	Grade 1-2	Grade 3	Grade 4	Grade 5
Valrubicin	19%	0%	0%	0%
Adstiladrin (NF)	8.3%	0%	0%	0%
Pembrolizumab	10.9%	2%	0%	0%
Anktiva (NAI)	39%	3.7%	1.2%	1.2%
TLD1433	0%	0%	0%	0%

Thanks Eoganacht....All factors considered (our current 12 month CR at ~27% & 12 month ORR at 71% across 68 patients, excellent safety profile & likely high cost-effectiveness...considering we are a one/two-and-done treatment), the future looks bright for this company.

For me, this investment has always been about long-term benefits of investing in a promising business/science, not about daily share price.  With a BTD in hand, it should only be a matter of months before we can finally graduate from the inherent chronic syndrome of false perception/categorization of microcap start-ups as a whole (many of which peddle promise w/o having the goods) that litter this high-risk & manipulated venture exchange...JMHO.  Good luck...

Thanks Eoganacht & CancerSlayer...

In the article provided the conclusion is very interesting.

5.Conclusions...
It said...'' Recent FDA -approved drugs, such as NF(Adstiladrin) and Pembrolizumab(keytruda), might be effectives alternatives to RC(radical cystectomy) in selected patients, achieving a good balance between cost, effectiveness, toxicity, and quality of life''.

Pembrolizulab(Keytruda) 18.9% CR at 450 days and a ton of side effects.

NF(Adstiladrin) 23.5% CR at 450 days,can't treat immune deficients patients, has 289 major drugs interactions, need a treatment every 3 months(4 time a years).

TLT-Ruvidar 36%CR at 450 days(53% more potent than Adstiladrin), no side effects, no restrictions, a one and done treatment.

Both Keytruda and Adstiladrin did receive the FDA BTD approval.
NOTE 1: We could say that these 2 treatments did receive the FDA BTD because of a lack of better treatments.
NOTE 2: You have to ask yourself, what a Big Pharma think of the above Ruvidar impressive numbers.



I love my TLT shares.

.